Table 1 Baseline characteristics in the survival and death groups of patients with PH.
Survived (n = 14) | Did not survive (n = 4) | P-value | |
|---|---|---|---|
Patient information | |||
Gender (male) | 8 (57.1%) | 2 (50.0%) | 1.000 |
GA (weeks), median (IQR) | 38.0 (37.5–38.9) | 36.3 (32.4–38.7) | 0.420 |
Preterm (< 37 weeks GA) | 3 (21.4%) | 2 (50.0%) | 0.533 |
BW (kg), median (IQR) | 3.0 (2.5–3.4) | 2.4 (1.5–2.9) | 0.089 |
Low BW (< 1500 g) | 3 (21.4%) | 2 (50.0%) | 0.533 |
BL (cm), median (IQR) | 48.5 (46.8–50.0) | 44.0 (40.8–48.8) | 0.146 |
BH (cm), median (IQR) | 34.0 (32.5–35.0) | 32.5 (28.4–34.0) | 0.186 |
BC (cm), median (IQR) | 32.0 (30.0-33.3) | 28.5 (25.5–31.5) | 0.097 |
1-min Apgar | 8.0 (7.0–10.0) | 7.5 (5.3–9.8) | 0.440 |
Low Apgar score (< 7) | 2 (14.3%) | 2 (50.0%) | 0.197 |
5-min Apgar | 10.0 (9.8–10.0) | 9.5 (8.25-10.0) | 0.311 |
Intubation at birth | 1 (7.1%) | 2 (50.0%) | 0.108 |
GO | 11 (78.6%) | 4 (100%) | - |
Content of omphalocele | |||
Liver | 11 (78.6%) | 4 (100%) | - |
Stomach | 5 (35.7%) | 3 (75.0%) | 0.275 |
Spleen | 3 (21.4%) | 2 (50.0%) | 0.533 |
Stage closure | 9 (64.3%) | 4 (100%) | - |
Maternal Information | |||
Maternal age (years) | 30.0 (27.5–36.3) | 29.5 (26.5–31.8) | 0.749 |
Adverse pregnancy | 1.0 (0–2.0) | 1.5 (1.0-2.8) | 0.379 |
Pregnancy-induced hypertension | 1 (7.1%) | 1 (25.0%) | 0.405 |
Gestational diabetes | 2 (14.3%) | 2 (50.0%) | 0.197 |
Medication use in pregnancy | 9 (64.3%) | 2 (50.0%) | 1.000 |
PH | |||
Age at diagnosis (days) | 3.5 (2.8–9.5) | 2.5 (2.0-4.5) | 0.232 |
Pulmonary vasodilator therapy | |||
Age at therapy (days) | 7.5 (4.8–19.0) | 5.5 (3.3–9.3) | 0.394 |
Nitric oxide | 2 (14.3%) | 1 (25%) | 1.000 |
Sildenafil | 13 (92.9%) | 4 (100%) | - |
Bosentan | 7 (50%) | 0 | - |